secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001099800-23-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q3 sales $1.48B (+12%), EPS $0.63; TAVR grows 11%; guidance reaffirmed
------------------------------------------------------------------------------

- Q3 revenue $1.48B (+12% reported, +11% constant currency); GAAP EPS $0.63, adjusted EPS $0.59.
- TAVR sales $961M (+11%); TMTT sales $52M on PASCAL Precision adoption; Surgical $247M (+12%).
- Adjusted gross margin 76.4% vs 81.0% a year ago on FX headwinds; FY2023 guidance reaffirmed (10-13% CC sales growth, adj. EPS $2.50-$2.60).
- Regulatory milestones: EVOQUE CE Mark (first transfemoral tricuspid replacement), PASCAL Precision approved in Japan, SAPIEN M3 pivotal trial enrollment completed.
- Free cash flow $356M; $174M share repurchased in Q3; cash & short-term investments $1.9B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/0001099800-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/ew-20231025.htm
  HTML page:      https://secwatch.observer/filing/0001099800-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer